{"id":"W3171995199","doi":"10.1200/jco.2021.39.15_suppl.2593","title":"Nivolumab/ipilimumab primed immunotransplant in post-CAR-T and post-ASCT DLBCL.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Ipilimumab; Fludarabine; Nivolumab; Neutropenia; Internal medicine; Cyclophosphamide; Progressive disease; Chemotherapy; Refractory (planetary science); Oncology; Gastroenterology; Immunotherapy; Cancer; Biology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008120118,0.0005865076,0.0007558135,0.0002087029,0.0002644314,0.0005075142,0.0004632441,0.0006001942,0.001436628],"category_scores_gemma":[0.0002349218,0.0002457349,0.0004386222,0.0002397616,0.000538962,0.0004110249,0.0002187548,0.001859928,0.0004315691],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008058501,"about_ca_system_score_gemma":0.0009944703,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008033009,"about_ca_topic_score_gemma":0.001725759,"domain_scores_codex":[0.9997832,0.00006976582,0.00001369326,0.00004012983,0.00002013447,0.00007299746],"domain_scores_gemma":[0.9997949,0.00002990675,0.0000239142,0.00002101079,0.000007454027,0.0001227232],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"case_report","study_design_scores_codex":[0.4163389,0.1373847,0.03486275,0.0009736914,0.000638983,0.001745374,0.0004324043,0.003435782,0.2234047,0.0005835608,0.003579274,0.1766199],"study_design_scores_gemma":[0.08882101,0.8070084,0.05195675,0.00005292065,0.0004363894,0.002172106,0.0001108709,0.003283542,0.04009961,0.0002345154,0.005791929,0.00003197262],"study_design_candidate":"case_report","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9972273,0.0008292172,0.0002382527,0.0000742462,0.00003732241,0.0004679643,0.0001963188,0.00003631071,0.0008930202],"genre_scores_gemma":[0.9982781,0.0002573199,0.0003132353,0.000120662,0.00002698217,0.000241819,0.0003776877,0.000004843771,0.0003792506],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001436628,"threshold_uncertainty_score":0.005846918,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09142502707162185,"score_gpt":0.4643852496822118,"score_spread":0.3729602226105899,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}